Identification of New Candidate Biomarkers to Support Doxorubicin Treatments in Canine Cancer Patients

Kristine Walters  
University of Minnesota

Alessia Stornetta  
University of Minnesota

Foster Jacobs  
University of Minnesota

Peter Villalta  
University of Minnesota

Maria Razzoli  
University of Minnesota

Marianne Grant  
University of Minnesota

Beshay Zordoky  
University of Minnesota

Alessandro Bartolomucci  
University of Minnesota

Antonella Borgatti  
University of Minnesota

Silvia Balbo (✉ balbo006@umn.edu)  
University of Minnesota

Research Article

Keywords: DNA Adducts, Adductomics, Doxorubicin, Predictive Biomarker, Precision Medicine, Veterinary Oncology

DOI: https://doi.org/10.21203/rs.3.rs-224712/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

**Background:** Human and veterinary cancer chemotherapy are undergoing a paradigm shift from a “one size fits all” approach to personalized, patient-oriented treatment strategies. Personalized chemotherapy is dependent on the identification and validation of biomarkers that can predict treatment outcome and/or risk of toxicity. Many cytotoxic chemotherapy agents, including doxorubicin, base their mechanism of action by interaction with DNA and disruption of normal cellular processes. We developed a high-resolution/accurate-mass liquid chromatography-mass spectrometry DNA screening approach for doxorubicin-induced DNA modifications (adducts) *in vitro* and *in vivo*. We used, for the first time, a new strategy involving the use of isotope-labeled DNA, which greatly facilitates adduct discovery. The overall goal of this work was to identify doxorubicin-DNA markers to be used as tools to predict drug efficacy for use in veterinary oncology.

**Results:** We used our novel mass spectrometry approach to screen for adducts in purified DNA exposed to doxorubicin. This initial *in vitro* screening identified nine potential doxorubicin-DNA adduct masses, as well as an intense signal corresponding to DNA-intercalated doxorubicin. Two of the adduct masses, together with doxorubicin and its metabolite doxorubicinol, were subsequently detected *in vivo* in liver DNA extracted from mice exposed to doxorubicin. Finally, the presence of these adducts and analytes was explored in the DNA isolated from dogs undergoing treatment with doxorubicin. The previously identified nine DOX-DNA adducts were not detected in these preliminary three samples collected seven days post-treatment, however intercalated doxorubicin and doxorubicinol were detected.

**Conclusions:** This work sets the stage for future evaluation of candidate DNA-related markers as biomarkers to personalize chemotherapy protocols for canine cancer patients. It demonstrates our ability to combine in one method the analysis of DNA adducts and DNA-intercalated doxorubicin and doxorubicinol, which interestingly, were persistent in samples from canine patients undergoing doxorubicin chemotherapy seven days after treatment. The presence of doxorubicin in all samples suggests a role for it as a promising biomarker for use in veterinary chemotherapy. Future studies will involve the analysis of more samples from canine cancer patients to elucidate optimal timepoints for monitoring doxorubicin-DNA adducts and the correlation of these markers with therapy outcome.

Introduction

Traditionally, cancer has been treated as a homogenous disease with chemotherapeutic treatment decisions based on tumor location, histopathologic findings, and expected biologic behavior (1). However, genetic variations in patients can result in different responses to therapy and varying degrees of toxicity, despite phenotypically similar diseases (2, 3). For these reasons, cancer chemotherapy is currently shifting from the concept of “one size fits all” to more personalized, patient-oriented approaches, with the goal of optimizing individual therapeutic protocols to increase treatment success (1).
Personalized chemotherapy is based on the ability to identify and target a patient subpopulation, predict drug efficacy, patient response, and likelihood of toxicity. The identification and validation of predictive biomarkers, robust chemical or molecular indicators of the outcome selected, is essential for identifying those patients who will most likely benefit from a drug regimen or will need a dose modification from the standard dosage (4, 5). There are multiple reports of identification and use of predictive biomarkers with traditional chemotherapeutics in a variety of cancer types including, but not limited to, colorectal, breast, pancreatic and lung cancers (6-9). Clinically, however, biomarkers are most commonly used to select patients for treatment with targeted therapies including monoclonal antibodies and small molecule inhibitors, but have not yet been implemented to guide treatment with traditional cytotoxic chemotherapy (10-12).

Patient-oriented treatment approaches have recently become of interest for use with veterinary patients, where the treatment goal is to provide a good quality of life while extending patient survival (13). In veterinary medicine, there is sparse information regarding biomarker development and use, and there are no predictive biomarkers used routinely. Similarly, the use of personalized chemotherapy in veterinary patients is limited, the closest example of which is the use of a receptor tyrosine kinase inhibitor, Toceranib (Palladia), in therapies for treatment of canine cutaneous mast cell tumors (14). Biomarker development and application of personalized chemotherapy approaches in veterinary medicine is of particular interest in guiding the practice of dose escalation of routinely used chemotherapeutic drugs (15, 16). By identifying predictive biomarkers of patient response, dose escalation strategies can be modified for each individual to benefit both those who are more likely to respond to the drug used and those who are likely to have a poor response or higher risk of treatment-associated side effects. Research has investigated the pharmacokinetics of chemotherapeutics in relation to the risk of myelotoxicity (17, 18), but these strategies have not been clinically adopted for use in personalized veterinary chemotherapy.

Doxorubicin (DOX, Fig. 1), a member of the anthracycline group of compounds, has good anticancer activity against a wide spectrum of tumors including hematopoietic neoplasia, sarcomas, and carcinomas.

It is currently one of the most extensively used chemotherapeutic drugs in canine clinical settings (19, 20). Treatment with DOX is not universally effective and may lead to adverse events, including dose-dependent cardiotoxicity. The intensity of these adverse events varies from patient to patient (19, 20). Given its extensive use in cancer therapy, the development of predictive biomarkers is of particular relevance for management of DOX chemotherapy. The key component of the mechanism of action (MOA) of DOX is the poisoning of topoisomerase II through intercalation into DNA, but other cellular responses have been shown to contribute to its MOA, including the formation of DNA modifications (adducts) (21, 22).

DNA adducts from anticancer DNA alkylating drugs have been shown to be good candidate predictive biomarkers of drug efficacy (23). Monitoring these adducts as predictive biomarkers has the advantage
of providing an integrative measure of patient-specific responses, since they account for an individual's absorption, distribution, metabolism, elimination and DNA repair (23). Furthermore, drug-DNA adducts may be more suitable biomarkers, as compared to non-drug related metabolites because of their specificity (23). The direct interaction of DOX with DNA creates an excellent opportunity for evaluating DOX-DNA adducts as predictive biomarkers. Previous *in vitro* studies have characterized a single DOX-DNA adduct generated in the presence of formaldehyde (24, 25), but to our knowledge, this or any other DOX-DNA adducts have yet to be detected *in vivo*.

Detection of DNA adducts in chemotherapy patients can be especially challenging because adducts develop at low levels beyond the typical detection limits achieved by traditional low-resolution spectral detection and high analytical flow rates liquid chromatography-mass spectrometry (LC-MS) methods (26, 27). We previously developed a nanoLC-MS$^3$ DNA adductomics approach that allows for the screening of potentially every adduct in a hydrolyzed DNA sample. This method is based on high-resolution/accurate-mass (HRAM) data-dependent constant neutral loss monitoring of the 2'-deoxyribose or one of the four DNA bases (guanine (G), adenine (A), thymine (T), and cytosine (C) (28, 29). The accurate mass measurement of an observed DNA adduct can be used for determining its elemental composition, whereas the triggered MS$^2$ and MS$^3$ fragmentation spectra provide structural information of the modified base. In addition, the use of nanoflow (300 nL/min) and nanoelectrospray increases sensitivity by providing increased ionization and sampling efficiency (28, 29). The goals of our study were to optimize our adductomics approach to screen for DOX-DNA adducts *in vitro* and *in vivo* and to identify candidate predictive biomarkers of DOX efficacy for future investigation in clinical studies.

**Results**

**Screening for DOX-DNA adducts *in vitro***

Initial screening for DOX-DNA adducts was performed by reacting DOX in the presence of formaldehyde with DNA from calf thymus (ctDNA) and with DNA extracted from *E.coli* bacteria. In order to facilitate adduct detection, we implemented a new strategy based on the use of $^{15}$N-isotope-labeled DNA, generated in *E.coli* bacteria, to be paired with $^{14}$N unlabeled *E.coli* bacterial DNA. Both DNA species are subjected to the same DOX exposure and sample preparation protocols, and then the two samples ($^{14}$N- and its counterpart $^{15}$N-bacterial DNA) are combined in a 1:1 ratio prior to LC-MS analysis. In this resulting combined sample, DNA adduct detection is based on the selection of only masses that triggered an MS$^3$ fragmentation event in the drug-exposed DNA samples, and were present as a matching pair of $^{14}$N-DNA and the $^{15}$N-DNA adducts, resulting in co-eluting peaks when extracted in the full scan chromatogram (this concept is explained in Fig. 2A).

A total of nine DNA adduct masses were detected in ctDNA and $^{14}$N- and $^{15}$N-bacterial DNA exposed to DOX (Table 1 and Fig. 2B).
Table 1. DOX-DNA adduct masses detected by untargeted screening from reaction of DOX with purified DNA in the presence of formaldehyde. Only the masses that triggered an MS³ fragmentation event in the DOX-exposed samples, but not in the negative control samples (unreacted DNA and buffer and enzymes used for the DNA hydrolysis) are reported. dR, 2'-deoxyribose, A, adenine, G, guanine, C, cytosine.

These masses were detected upon neutral loss of dR, G, A or C. The most frequent neutral loss observed was dR, followed by G, observed five and three times, respectively. Overall, the majority of the adducts were evenly distributed over the 44 min. chromatographic gradient (Fig. 2B). Two pairs of masses, however, eluted at the same retention time (RT, in Table 1 No. 2 and 3, and No. 7 and 9), suggesting that the pair belongs to the same molecule, and the lower mass is most likely the product of in-source fragmentation of the higher mass in the mass spectrometer.

In the first pair of masses, m/z 531.2062, was detected by neutral loss of dR resulting in a fragment ion of mass m/z 415.1577, which in turn triggered two MS³ fragmentation events upon neutral loss of guanine and dR, suggesting that this adduct is a crosslink comprising two dR moieties. Indeed, masses m/z 531.2062 and 415.1577 were assigned to a previously detected crosslink formed by a deoxyguanosine, formaldehyde, and deoxyadenosine (dG-CH₂-dA) (30).

The second pair of masses, m/z 809.2622 and 680.1830 (Fig. 3A) differed by 129.0792 amu, which corresponds to the exact mass of the aminosugar of DOX (Fig. 1).

We believe that m/z 680.1830 results from in-source fragmentation of the aminosugar from m/z 809.2622. Interpretation of the resulting MS² and MS³ spectra suggests that this is a nucleoside adduct involving guanine, and that the aminosugar moiety of DOX, which is partly lost in the MS source, is not
the moiety that reacts with DNA, as reported previously (Fig. 3B) (21). We hypothesize that the reduction of the quinone to a semiquinone results in a radical that adds to either the C4-, C5-, C8- or, to a much lesser extent, to the C2-position of guanine (31). The chemical synthesis and characterization, and the matching of identical fragmentation spectra, is necessary for unequivocal adduct identification and will be the focus of future studies.

**Time course of formation and persistence of DOX-DNA adducts *in vivo***

The presence of the DOX-DNA adducts detected *in vitro* was then investigated *in vivo* using a targeted MS/MS approach in DNA extracted from liver samples harvested from mice exposed to two different DOX regimens and followed over time. In the first regimen, mice were acutely exposed to DOX, whereas in the second regimen, mice received a low dose of DOX once a week for 3 weeks. The samples from these studies were used to assess the kinetics of formation of the DOX-DNA adducts and their persistence over time, considering various time points after drug administration.

In addition to the DOX-DNA adducts, our *in vitro* screening of hydrolyzed DNA samples revealed the presence of a very intense full scan peak with *m/z* 544.1813. This mass corresponds to the molecular ion of DOX (calculated *m/z* of 544.1813), suggesting that DOX is still intercalated in the DNA after sample purification using chloroform/isoamyl alcohol. In light of this finding, our targeted MS/MS approach also included the masses of DOX and, to account for metabolism, DOX's major metabolite doxorubicinol (DOXol, *m/z* 546.1970, Fig. 1) (19). DOX was detected in hydrolyzed DNA extracted from the liver of mice exposed for 24, 48, and 96 h, whereas DOXol was also detected in all three samples, but at an intensity that was about 150-350-fold lower than DOX, assuming similar ionization efficiency and recovery (Fig. 4).

Interestingly, DOX was still present in hydrolyzed DNA isolated from mouse liver one and three weeks post-drug exposure (Fig. 4), and at levels that were more than 2000-times above our limit of detection (LOD) of 33.3 fmol on-column (measured by triplicate injection of decreasing concentrations of DOX in matrix).

Due to the presence of DNA-intercalated DOX and DOXol in these samples, we considered the possibility that leftover DNA-intercalated drug is reacting with DNA bases during hydrolysis and sample cleanup, resulting in *in situ* adduct formation. We first attempted to remove the intercalated DOX from the DNA by performing 5 or 10 liquid/liquid extractions with phenol/chloroform/isoamyl alcohol, but this was shown not to be sufficient at removing the drug from the DNA (data not shown). Subsequently, $^{15}$N-labeled DNA in amounts equal to what was extracted from the mouse livers was added to the samples prior to DNA hydrolysis to check for adduct formation during sample preparation.

Two of the previously detected DOX-DNA adduct masses (*m/z* 680.1830 and 809.2622 in Table 1) were detected in liver DNA of mice exposed to DOX (Fig. 5A, plot a and c).

Interestingly, their $^{15}$N-labeled counterparts were also present, suggesting that these two masses are also formed during sample processing (Fig. 5A, plot b and d). The time course of formation over 96 hour
exposure of these two masses (and their $^{15}$N-labeled counterparts) showed similar levels and trends for each drug exposure duration, suggesting that this adduct is mostly formed during sample processing rather than *in vivo* during drug exposure (Fig. 5B). These two DOX-DNA adduct masses were not detected in the liver DNA samples of mice after one or three weeks from treatment with DOX.

**Detection of DOX-adducts, DOX and DOXol in DNA isolated from blood of canine cancer patients**

Previously detected DOX-DNA adducts (Table 1), DOX and DOXol were targeted (MS/MS) for detection in DNA isolated from three canine patients receiving DOX as part of a multiagent chemotherapy protocol called CHOP (Cyclophosphamide, Hydroxydaunorubicin (DOX), Oncovin (vincristine), and Prednisone). A single blood sample (about 3 mL) was collected from each canine patient one week post-treatment with DOX, when dogs returned to the clinic for a post-chemotherapy complete blood count (CBC) per routine protocol at our hospital (Table S1).

Blood samples collected from two dogs who did not receive DOX were used as a negative control. Extracted DNA amounts ranged from 90 to 200 µg. None of the previously observed DOX-DNA adducts were detected in the samples. DOX was detected in the DNA isolated from all three exposed dog blood samples, whereas DOXol was detected in the DNA of two out three samples (Fig. 6).

**Discussion**

In this study, we applied our LC-MS$^3$ adductomics approach to screen for DNA adducts induced by the anticancer drug doxorubicin (DOX) and tested their potential to be used as predictive biomarkers of DOX efficacy in canine cancer patients. The main findings of this study are 1) a novel LC-MS$^3$-based approach that detects DOX-DNA adducts, DOX, and DOXol: 2) a list of DOX-DNA adduct masses detected *in vitro* and *in vivo*; 2) information about the persistence over time of DNA-intercalated DOX and doxorubicinol, in mice receiving DOX and canine cancer patients undergoing DOX treatment; and 4) identification of promising analytes to be developed as predictive biomarkers to support DOX treatment and to be validated for future use in veterinary oncology.

In cancer chemotherapy, precision medicine-based approaches using biomarkers of efficacy are being developed to predict a patient’s response to the treatment. Previous studies have shown promise for the use of predictive biomarkers as an alternative to more conventional dose-determining methods. However, in veterinary medicine, there are limited examples that have been demonstrated, but are not commonly used clinically. For example in cats undergoing chemotherapy, a biomarker-based personalized approach for treatment with carboplatin better predicted myelosuppression than dosing based on body surface area (18). The serum concentration-time curve (AUC) for Doxorubicin (DOX) has also been found to be predictive of the reduction of total white blood cell and neutrophil counts in dogs (17).

In the case of DNA adducts as predictive biomarkers, various studies have investigated in humans the relationship between DNA adducts and patient treatment outcome (23). One study found that by measurement of the interstrand DNA cross-link G-NOR-G, it was determined that Fanconi anemia (FA)
patients are hypersensitive to the anticancer drug cyclophosphamide and require a lower dose of the drug compared to non-FA patients prior to hematopoietic cell transplantations (32). Another study found that out of seven patients being treated for multiple myeloma, the three with the lowest levels of DNA adducts in TP53 and N-ras gene sequences did not respond to treatment with melphalan (33).

With regards to platinum-based chemotherapy, higher levels of platinum-DNA adducts have been observed in isolated leukocyte DNA in patients with good clinical outcome when being treated for ovarian and testicular cancer with cisplatin or carboplatin (34-36). Platinum-DNA adduct formation has also been found to correlate significantly with patient response following treatment for non-small-cell lung cancer with cisplatin (37). In a study that investigated Oxaliplatin, it was observed that platinum-DNA adduct levels in peripheral blood mononuclear cells correlated significantly to mean tumor volume change (38). Finally, carboplatin-DNA adduct levels following diagnostic microdoses have been investigated for their potential to predict patient response prior to treatment with the therapeutic dose (39).

Our in vitro screening approach, which resulted in the detection of nine DOX-DNA adduct masses (Table 1), was improved by using a novel strategy involving the pairing of $^{14}$N- and $^{15}$N-labeled DNA (Fig. 2A). This novel strategy facilitates adduct detection and can be applied for in vitro identification of DNA adducts resulting from any type of exogenous exposure, such as other DNA alkylating anticancer drugs, as well as tobacco-specific, dietary, and environmental chemicals.

Early studies reported the detection, in vitro, of a DNA adduct formed at the N$^2$-position of guanine that involved formaldehyde to link the DNA to the aminosugar of DOX (21). This adduct was not detected in vitro by our approach. We hypothesize that the previously reported poor stability of this adduct in DNA (21) makes its detection in hydrolyzed samples and using our approach and current conditions challenging. In an effort to make this adduct more stable, we performed a reduction using sodium cyanoborohydride (40), however the adduct was not detected in its reduced form (data not shown).

Additionally, an interesting finding from our in vivo adduct detection was the formation of adducts during sample preparation. We hypothesize that the release of DOX in the solution, as a consequence of the DNA being hydrolyzed, results in its reaction with free nucleosides to form DNA adducts. To our knowledge, there is no information currently available about the reactivity of DOX with free nucleosides, suggesting that the nature of this reaction as well as the persistence of DNA-intercalated DOX needs further characterization. If adduct formation is greater when DOX is released from the DNA (such as during enzyme hydrolysis), it is possible that in vivo adduct formation takes place in the course of DNA replication, during which the double helix opens up to allow for the synthesis of a new DNA strand and the intercalated DOX is released. Furthermore, adduct formation during sample processing seems to be solely a characteristic of those drugs that are able to intercalate to DNA, but not of drugs whose structure does not allow for such intercalation. Indeed, a complete removal from the DNA of the anticancer drug cyclophosphamide is possible when using similar sample preparation protocols and in situ formation of adducts during DNA hydrolysis is not observed (data not shown). Understanding if this is a feature of all drugs or molecules that intercalate to DNA will be the focus of future work.
To verify the presence of the DOX-DNA adducts, DOX, and DOXol in a sample type that would be available for biomarker monitoring in the clinic, we analyzed DNA isolated from blood collected from dogs undergoing chemotherapy treatment that included DOX (seven days post-treatment). Because none of the previously observed adducts were detected in these samples, we hypothesize that too much time has passed between sample collection and treatment, and therefore levels of adducts were most likely below the limit of detection of our approach. On the other hand, DOX and DOXol were detected in the DNA extracted from these samples (Fig. 6). The ability of our approach to measure DOX in DNA from patient samples using as little as 3 mL of blood demonstrates the feasibility of using intercalated DOX as a potential predictive biomarker of efficacy. A different study reported an assay for quantification of DOX intercalated with DNA in tumor and tissues using HPLC (41). In comparison, our LC-MS DNA adductomics approach has the advantage of providing a combined measurement of DOX-DNA adducts, DOX and DOXol, as well as structural information through fragmentation spectra which can be used to confirm the structure of anticipated molecules, identify the structures of new ones, and facilitates peak assignment in the absence of an isotope-labeled internal standard.

Conclusions

The adoption of personalized approaches in veterinary oncology has the potential not only for increased treatment success, but also to be more cost-effective as cancer chemotherapy for animals can be expensive. Our study provides new insights on promising potential DNA markers to be developed as predictive tools in canine cancer treatment with DOX. To our knowledge, this is the first study using our DNA adductomics screening approach for the combined analysis of a clinically used drug and its derived DNA adducts. We demonstrated the ability of our method to monitor DOX in DNA isolated from blood collected from canine cancer patients seven days post-treatment, suggesting that DNA-intercalated DOX may also be developed as a predictive biomarker of drug efficacy. Future efforts will validate these markers to select veterinary patients that will benefit from chemotherapy using DOX and to develop personalized chemotherapy protocols aimed at improving quality of life of canine cancer patients.

Methods

Reagents and chemicals

Cell lysis, Proteinase K, and RNase A solutions were purchased from QIAGEN. DNA purified from calf thymus (ctDNA) was purchased from Worthington Biochemical Corporation, C\textsubscript{3}H\textsubscript{8}O and CH\textsubscript{3}OH were purchased from Honeywell, and CH\textsubscript{2}O (37%), MgSO\textsubscript{4}, and CaCl\textsubscript{2} were purchased from Thermo Fisher Scientific. All other chemicals, materials and enzymes were purchased from Millipore Sigma. All solvents used for chromatography and mass spectrometry analyses were of the purest commercially available grade.

Generation of isotope-labeled DNA from \textit{E.coli}


\[ 15\text{N}-\text{labeled bacterial DNA was generated by growing}\ E.\ coli \ (\text{MG1655 strain}) \ \text{in M9 minimal medium (standard) fortified with}\ 15\text{NH}_4\text{Cl. 98% DNA labeling was achieved by growing the bacteria for at least three generations. Briefly, 10}\ \mu\text{L} \ \text{of bacterial stock culture in 25% glycerol were inoculated in 5 mL M9 minimal media started culture and incubated overnight in a thermoshaker (37 °C, 200 rpm). Afterwards, 50}\ \mu\text{L} \ \text{of cells from the starting culture were added to 1 L M9 minimal medium containing}\ 15\text{NH}_4\text{Cl and further incubated in the thermoshaker (37 °C, 200 rpm) until an optical density (measured by absorbance at 600 nm) of 1.2 absorbance units was reached. The culture was then split in 50 mL volumes, and the cells were pelleted by centrifugation at 4,000 x g for 10 min. Cell pellets were stored at -80 °C. The same protocol was performed in parallel for generating bacterial DNA that did not contain the}\ 15\text{N}-\text{isotope.}}\]

**Extraction of bacterial DNA**

Cell pellets were vortexed and re-suspended in the remaining liquid. Three 50 mL Eppendorf tubes containing \( 15\text{N-DNA} \) were combined into one 50 mL Eppendorf tube and 25 mL of cell lysis solution was added. Next, 150 \( \mu\text{L} \) Proteinase K were added followed by overnight incubation in the shaker at room temperature. A total of 7.5 mL of protein precipitation solution was added and vortexed for 20 s followed by incubation on ice for 10 min. The solution was then centrifuged (4000 x g for 10 min) and the remaining supernatant was divided evenly into two parts (~16.25 mL) and each were poured into clean Eppendorf tubes containing 17 mL cold isopropanol (IPA) to allow the DNA to precipitate. The precipitated DNA pellet was transferred in a clean, silanized glass vial and subsequently washed using 3 mL 70% IPA and 3 mL 100% IPA. Pellets were air-dried and subsequently combined into one 50 mL Eppendorf tube.

The DNA was re-suspended in 10 mL 10 mM PIPES/5 mM MgCl\(_2\). A total of 150 \( \mu\text{L} \) RNase A was added followed by incubation at 37 °C for 2 h. A total of 5 mL protein precipitation solution was added followed by 20 s of vortexing, 5 min incubation on ice, and centrifugation for 10 min at 4000 x g. DNA precipitation was performed by addition of 2 mL cold IPA to each vial. The precipitated DNA was removed from the sample, placed in a clean, silanized glass vial, and washed twice with 1 mL 70% IPA and 1 mL 100% IPA. DNA pellets were air-dried and stored at -20 °C.

**Reaction of calf thymus DNA (ctDNA) or isotope-labeled bacterial DNA with DOX**

DOX (100 \( \mu\text{L}, 0.6 \text{ mg/mL}) \text{ in Tris-HCl buffer (10 mM, pH 7.4) was added to a reaction mixture containing formaldehyde (500 \( \mu\text{L}, 300 \mu\text{M}) \text{ in water and either ctDNA (400 \( \mu\text{L}, 2.5 \text{ mg/mL}), 14N-bacterial DNA (500 \( \mu\text{L}, 1 \text{ mg/mL}) \text{ or } 15N-bacterial DNA (500 \( \mu\text{L}, 0.8 \text{ mg/mL}) \text{ in Tris-HCl buffer (10 mM, pH 7.4). The reaction mixtures were incubated at 37 °C for 24 h. The same reaction mixtures without DOX were used as negative controls. Isolation of DNA was performed by IPA precipitation. Briefly, 2 mL cold IPA were added to each vial. The precipitated DNA was removed from the sample, placed in a clean, silanized glass vial, and washed twice with 1 mL 70% IPA and 1 mL 100% IPA. The DNA pellet was dried under a nitrogen stream. All of the steps of this procedure were performed in silanized glass vials.}**
Animal Ethics

All procedures involving live vertebrates, including both mouse and canine patients, were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota and were carried out in accordance with relevant guidelines and regulations. Additionally, all animal studies, both murine and canine, were performed in compliance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (42).

Mouse treatment

Single dose: Adult male C57BL/6J mice were administered with a 10 mg/kg intraperitoneal injection of DOX or sterile saline vehicle. This dose was selected upon literature evaluation of similar studies involving an acute administration of DOX (43-46). Mice were then sacrificed 24, 48, or 96 h following DOX injection (n=2/time point). Control mice (n=2) were sacrificed 48 h following vehicle injection. The liver and blood were harvested and stored at -80 °C.

Weekly dose: Five week old male C57BL/6N mice (n=3/group) were administered once a week with DOX 4 mg/kg/week or equivalent volume of sterile saline vehicle by intraperitoneal injection for 3 weeks as we previously reported (47). Animals were sacrificed at designated time points (1 or 3 weeks) after the last injection. Liver and blood samples were collected and stored at -80 °C.

Isolation of DNA from liver tissue samples

Genomic DNA from mice exposed to DOX was extracted with the QIAGEN Gentra Puregene Tissue Kit (Qiagen Sciences) following the manufacturer's instructions with minor modifications. In brief, frozen liver tissues (270-390 mg) were minced with a razor blade while on dry ice. The minced tissues were lysed with 3 mL cell lysis solution and incubated for 5 min on ice to allow for degradation. The tissue was then homogenized using a tissue homogenizer set at low-medium speed for no more than 1 min. Additional 3 mL of cell lysis solution were added and mixed by inverting 25 times. Next, 30 µl of Puregene Proteinase K were added and tubes were mixed by inverting 25 times and incubated overnight in a shaker at room temperature. RNase A solution (30 µl) was added to each lysate and mixed before incubation for 2 h in a shaker at room temperature. Then, 2 mL of protein precipitation solution were added and tubes were vortexed vigorously for 20 s prior to centrifugation (2500 x g for 15 min). Supernatants were added to cold IPA, and DNA was precipitated and washed as previously described, with the only difference being the DNA pellets were air-dried. The DNA pellets were stored at -20 °C. The amounts described above were reduced by a factor of 4 when using 50 mg of liver tissue.

Recruitment and Sample Collection from Patients Undergoing Chemotherapy with Doxorubicin

Dogs with spontaneously arising tumors of various histologies undergoing treatment with a DOX-based chemotherapy protocol at the University of Minnesota Veterinary Medical Center were recruited. Dogs eligible for enrollment had a constitutional clinical signs score of 0 or 1 according to the Eastern
Cooperative Oncology Group performance scale (48), body weight $\geq 10$Kg, and adequate hematologic, renal, and hepatic function. Following written informed consent of each dog owner, blood (6-10 mL, depending on dog's size) was collected via routine venipuncture into a potassium EDTA tube 7 days post-treatment with doxorubicin when dogs returned for their post-chemotherapy CBC per routine protocol at our institution.

**Isolation of DNA from blood tissue samples**

Genomic DNA was extracted with the QIAGEN Gentra Puregene Blood Kit following the manufacturer's instructions for DNA Purification from Whole Blood with minor modifications. In brief, 3 mL of whole blood were lysed with 9 mL red blood cell (RBC) lysis solution and mixed by inverting 10 times followed by 5 min of incubation at room temperature. Next, the solution was centrifuged for 2 min at 2,000 x g to pellet the white blood cells. The supernatant was then discarded leaving approximately 200 µL of residual liquid. The pellet was resuspended in the residual liquid by vortexing vigorously. A total of 3 mL of cell lysis solution was added and tubes were vortexed. RNase A solution (30 µl) was added to each lysate and mixed by inverting 25 times followed by 15 min of incubation at 37 °C, which was followed by 3 min of incubation on ice. Then, 1 mL of protein precipitation solution was added and the tubes were vortexed vigorously for 20 s prior to centrifugation (2000 x g for 5 min). Supernatants were added to cold IPA, and DNA was precipitated and washed as previously described, with the only difference being the DNA pellets were air-dried. The dried pellets were stored at -20 °C. The amounts described above were reduced by a factor of 6 when using about 0.5 mL of whole blood.

**DNA clean-up, hydrolysis and sample enrichment**

Prior to hydrolysis and adduct enrichment, purified DNA samples and mouse liver DNA from the acute treatment study were dissolved in 2 mL 10 mM Tris + 1 mM EDTA (pH 7.0). Then, 2 mL of chloroform/isoamyl alcohol (24:1, purified DNA samples) or phenol/chloroform/isoamyl alcohol (25:24:1, mouse liver DNA samples) was added and the solution was vortexed vigorously for 60 s followed by centrifugation (2,000 x g for 10 min), and the upper layer was collected and transferred into a clean 5 mL Eppendorf tube. The extraction was performed twice. After the second extraction, 200 µl 5 M NaCl were added. DNA was precipitated using cold IPA as previously described. The dried pellets were stored at -20 °C until further use. The extraction was performed in an attempt to remove leftover drug from the samples.

Prior to DNA hydrolysis, DNA was re-dissolved in a 10 mM Tris-HCl/5 mM MgCl$_2$ buffer (pH 7.4) solution. Initial digestion of DNA was performed overnight at room temperature by addition of 124 U/mg DNA (ctDNA and bacterial DNA) or 600 U/mg DNA (liver and blood DNA) DNase I (recombinant, from *Pichia pastoris*). Then, an additional 124 or 600 U/mg DNA, 6.6 mU/mg DNA (ctDNA and bacterial DNA) or 20 mU/mg DNA (liver and blood DNA) phosphodiesterase I (type II, from *Crotalus adamanteus* venom) and 46 U/mg DNA (ctDNA and bacterial DNA) or 240 U/mg DNA (liver and blood DNA) of alkaline phosphatase (recombinant, from *Pichia pastoris*) were added and samples were incubated at 37 °C for
70 min. and followed by overnight incubation at room temperature. Enzymes were removed by centrifugation using a Centrifree ultrafiltration device (MW cutoff of 30,000, Millipore Sigma) at 2000 x g for 45 min. A 10-15 µL aliquot was removed from each sample for dGuo quantitation.

Samples were desalted and enriched using a Strata-X solid phase extraction (SPE) cartridge (33 µm, 30 mg/1 ml, Phenomenex). Briefly, the cartridge was pre-conditioned and equilibrated with 3 mL CH₃OH and 1 mL H₂O. Samples were loaded, and the cartridge was washed with 3 mL H₂O and 1 mL 10% CH₃OH in H₂O. The two eluting fractions collected were 1 mL 100% CH₃OH and 1 mL CH₃OH + 2% formic acid. The fractions were evaporated until dry and stored at -20 °C. Prior to LC-MS analysis, samples were reconstituted in 500 µL (ctDNA), 250 µL (bacterial DNA) or 10 µL (liver and blood DNA) 5% CH₃OH in LC-MS grade water. For the DNA samples extracted from mouse liver and dog blood, the two SPE fractions were pooled together prior to LC-MS analysis.

**dGuo quantitation by HPLC-UV analysis**

Quantitation of dG was carried out on an UltiMate 3000 UHPLC System (Thermo Fisher Scientific) with a UV detector set at 254 nm. A 250 x 0.5 mm Luna C18 100A column (Phenomenex, Torrance, CA) at 40 °C was used with a flow rate of 15 µl/min and a gradient from 5% to 25% CH₃OH in H₂O over the course of 10 min followed by an increase to 95% CH₃OH in 3 min and a hold at 95% CH₃OH for 5 min. The column was re-equilibrated to initial conditions for 8 min.

**LC-MS parameters**

Samples were injected onto an UltiMate 3000 RSLCnano UPLC (Thermo Fisher Scientific) system equipped with a 5 µL injection loop. Liquid chromatography (LC) separation was performed on a capillary column (75 µm ID, 20 cm length, 10 µm orifice) created by hand packing a commercially available fused-silica emitter (New Objective) with 5 µm Luna C18 bonded separation media (Phenomenex). Gradient conditions were 1000 nL/min for 5.5 min at 5% CH₃CN in 0.05% formic acid aqueous solution, then decreased to 300 nL/min followed by a linear gradient of 1%/min over 44 min for the untargeted screening and over 30 min for the targeted MS/MS analysis. Column wash was performed with a flow rate of 300 nL/min at 98% CH₃CN for 5 min (untargeted screening) or at 95% CH₃CN for 2 min (targeted MS/MS analysis). Re-equilibration was performed with a flow rate of 1000 nL/min at 5% CH₃CN for 5 min (untargeted screening) or for 1 min (targeted MS/MS analysis). The injection valve was switched at 5.5 min to remove the sample loop from the flow path during the gradient. All MS data was acquired on an Orbitrap Fusion Tribrid Mass Spectrometer (Thermo Fisher Scientific). Positive mode electrospray ionization and nanospray (300 nL/min) were used on a Thermo Scientific Nanoflex ion source with a source voltage of 2.2 kV, a capillary temperature of 300 °C, a S-Lens RF level set at 60%, and EASY-IC lock mass (m/z 202.0777) enabled.

**Constant Neutral Loss (CNL)-MSⁿ data-dependent acquisition (DDA)**
CNL-MS$^n$ DDA was performed by repeated full scan detection followed by MS$^2$ acquisition and constant neutral loss triggering of MS$^3$ fragmentation. Full scan (range 200-2000 Da) detection was performed by setting the Orbitrap detector at 60,000 resolution with 1 microscan, automatic gain control (AGC) target settings of 2.0E5, and maximum ion injection time set at 50 ms. The most intense full scan ions were fragmented over a 2 s cycle. The MS$^2$ fragmentation parameters were as follows: quadrupole isolation window of 1.6, HCD collision energy of 20% ± 10%, Orbitrap detection at a resolution of 7,500, AGC of 2.0E5, 1 microscan, maximum injection time of 50 ms, and EASY-IC lock mass (m/z 202.0777) enabled. Data-dependent conditions were as follows: triggering intensity threshold of 2.5E4, repeat count of 1, exclusion duration of 30 s, and exclusion mass width of ± 5 ppm. The MS$^3$ fragmentation parameters were as follows: HCD fragmentation, 2 amu isolation window, collision energy of 20% ± 10%, Orbitrap detection at a resolution of 7,500 upon the observation of neutral losses (± 5 ppm) of 116.0474 (-dR), 151.0494 (-G), 135.0545 (-A), 126.0429 (-T), 111.0433 (-C), 156.0346 (-$^{15}$N-G), 140.0413 (-$^{15}$N-A), 128.037 (-$^{15}$N-T), or 114.0344 (-$^{15}$N-C) between the parent ion and one of the most intense product ions from the MS$^2$ spectrum, provided minimum signal of 2.5E4, AGC of 2.0E5, maximum injection time of 50 s, and EASY-IC lock mass (m/z 202.0777) enabled.

**Targeted data acquisition**

Targeted MS$^2$ acquisition was performed with a quadrupole isolation window of m/z 1.5 centered on m/z 609.2, 598.2, 735.2, 592.1, 619.2, 608.1, 743.1, 358.1, 376.1, 378.6, 470.2, 472.2, 363.1, 381.1, and 383.6 during the time span 0-14 min, m/z 541.2, 345.2, 356.2, 373.2, and 432.2 during the time span 12-20 min, m/z 415.2, 531.2, 340.2, and 425.1 during the time span 14-20 min, m/z 680.2, 809.3, 814.2, 685.2, 546.2, 544.2, and 791.9 during the time span 20-41 min, and m/z 823.3 during the time span 0-41 min. The other settings were: scan range 80-1000, HCD fragmentation of 20% ± 10%, Orbitrap detection at a resolution of 60,000, AGC of 5.0E4, 1 microscan, maximum injection time of 118 ms, RF lens set at 60% and EASY-IC lock mass (m/z 202.0777) enabled.

**List Of Abbreviations**

| Abbreviation | Description                          |
|--------------|--------------------------------------|
| A            | Adenine                              |
| AH$_2$O      | Adenine and Water (when referring to a neutral loss) |
| C            | Cytosine                             |
| CBC          | Complete Blood Count                 |
| CH$_3$OH     | Methanol                             |
| CHOP         | Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone |
| Acronym | Description |
|---------|-------------|
| CNL     | Constant Neutral Loss |
| ctDNA   | Calf Thymus DNA |
| dG      | Deoxyguanosine |
| DOX     | Doxorubicin |
| DOXol   | Doxorubicinol |
| dR      | 2’-Deoxyribose |
| EASY-IC | Easy Internal Calibration |
| EDTA    | Ethylenediaminetetraacetic acid |
| EIC     | Extracted Ion Chromatogram |
| FS      | Full Scan |
| G       | Guanine |
| GH₂O    | Guanine and Water (when referring to a neutral loss) |
| h       | Hour(s) |
| HRAM    | High-resolution/Accurate-mass |
| IE      | Iterative Exclusion |
| IPA     | Isopropanol |
| LC      | Liquid Chromatography |
| LLOQ    | Lower Limit of Quantitation |
| LOD     | Limit of Detection |
| min     | Minute(s) |
| MOA     | Mechanism of Action |
| MS      | Mass Spectrometry |
| ND      | Not Detected |
| NL      | Neutral Loss |
Declarations

Ethics approval and consent to participate

Animal procedures, both murine and canine, were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Minnesota and were carried out in accordance with relevant guidelines and regulations. Each owner provided written informed consent before the blood sample was taken from their dogs. Additionally, all animal studies, both murine and canine, were performed in compliance with the ARRIVE guidelines.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analyzed in the current study are available from the corresponding author upon reasonable request.

Competing interests

None

Funding

This research was funded in part by the University of Minnesota Small Companion Animal Grant awarded to KW. BZ is supported by the National Heart, Lung, and Blood Institute, grant 1R01HL151740, the St. Baldrick’s Foundation for Childhood Cancer (Award ID 638335); and the National Institutes of Health’s National Center for Advancing Translational Sciences, grant UL1TR002494. The funders had no role in the design of the collection, analysis, and interpretation of data.

Authors’ contributions
AS, FJ, PWV and SB conceived and planned the experiments, developed the methodologies used to analyze the samples, and performed data analysis and interpretation. AS, FJ, and KW conducted the experiments and were responsible for writing the manuscript. KW and ABo recruited the patients undergoing treatment with DOX. MR, ABa, MG, and BZ performed the animal studies and provided tissue samples. ABo and SB supervised the work. All authors have read and approved this manuscript, and they assisted in the final editing.

Acknowledgements

The authors would like to thank the owners of the dogs for participating in this study. Additionally, the authors would like to extend thanks to the nurses at the University of Minnesota Veterinary Medical Center who collected the blood samples from the patients, to Romel P. Dator for providing the bacterial DNA, and to Valeria Guidolin for providing data and insight regarding the use of the anticancer drug cyclophosphamide.

References

1. Van’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452(7187):564-70.
2. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479-85.
3. Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786-8.
4. Kellogg GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012;11(3):201-14.
5. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015;4(3):256-69.
6. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26(16):2690-8.
7. Paradiso A, Mangia A, Chiriatti A, Tommassi S, Zito A, Latorre A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005;16 Suppl 4:iv14-9.
8. Van der Sijde F, Vietsch EE, Mustafa DAM, Besselink MG, Groot Koerkamp B, van Eijck CHJ. Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. Cancers (Basel). 2019;11(1).
9. Villalobos P, Wistuba, II. Lung Cancer Biomarkers. Hematol Oncol Clin North Am. 2017;31(1):13-29.
10. Ascierto P, Kalos M, Schaer D, Callahan M, Wolchok J. Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. Clin Cancer Res. 2013;19(5):1009-20.
11. Selleck MJ, Senthil M, Wall NR. Making Meaningful Clinical Use of Biomarkers. Biomark Insights. 2017;12:1177271917715236.

12. Fuzery AK, Levin J, Chan MM, Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 2013;10(1):13.

13. Mealey KL, Martinez SE, Villarino NF, Court MH. Personalized medicine: going to the dogs? Hum Genet. 2019;138(5):467-81.

14. London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res. 2009;15(11):3856-65.

15. Vickery KR, Wilson H, Vail DM, Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet Comp Oncol. 2008;6(2):111-9.

16. Thamm DH, Gustafson DL. Drug dose and drug choice: Optimizing medical therapy for veterinary cancer. Vet Comp Oncol. 2020;18(2):143-51.

17. Wittenburg LA, Weishaar K, Ramirez D, Gustafson DL. Doxorubicin area under the curve is an important predictor of neutropenia in dogs with naturally occurring cancers. Vet Comp Oncol. 2019;17(2):147-54.

18. Bailey DB, Rassnick KM, Erb HN, Dykes NL, Hoopes PJ, Page RL. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors. Am J Vet Res. 2004;65(11):1502-7.

19. Thorn C, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein T, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440-6.

20. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267-85.

21. Cutts SM, Nudelman A, Rephaeli A, Phillips DR. The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005;57(2):73-81.

22. Tacar O, Srimornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157-70.

23. Stornetta A, Zimmermann M, Cimino GD, Henderson PT, Sturla SJ. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chemical Research in Toxicology. 2017;30(1):388-409.

24. Taatjes DJ, Gaudiano G, Resing K, Koch TH. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin. J Med Chem. 1997;40(8):1276-86.

25. Cullinane C, Cutts SM, van Rosmalen A, Phillips DR. Formation of adriamycin–DNA adducts in vitro. Nucleic Acids Res. 1994;22(12):2296-303.

26. Farmer PB, Brown K, Tompkins E, Emms VL, Jones DJ, Singh R, et al. DNA adducts: mass spectrometry methods and future prospects. Toxicol Appl Pharmacol. 2005;207(2 Suppl):293-301.
27. Nestmann ER, Bryant DW, Carr CJ. Toxicological significance of DNA adducts: summary of discussions with an expert panel. Regul Toxicol Pharmacol. 1996;24(1 Pt 1):9-18.

28. Balbo S, Hecht SS, Upadhyaya P, Villalta PW. Application of a high-resolution mass-spectrometry-based DNA adductomics approach for identification of DNA adducts in complex mixtures. Anal Chem. 2014;86(3):1744-52.

29. Stornetta A, Villalta PW, Hecht SS, Sturla SJ, Balbo S. Screening for DNA Alkylation Mono and Cross-Linked Adducts with a Comprehensive LC-MS3 Adductomic Approach. Analytical Chemistry. 2015;87(23):11706-13.

30. Hu C, Chang Y, Cooke M, Chao M. DNA Crosslinkomics: A Tool for the Comprehensive Assessment of Interstrand Crosslinks Using High Resolution Mass Spectrometry. Anal Chem. 2019.

31. Dizdaroglu M, Jaruga P. Mechanisms of free radical-induced damage to DNA. Free Radic Res. 2012;46(3):382-419.

32. Johnson LA, Malayappan B, Tretyakova N, Campbell C, MacMillan ML, Wagner JE, et al. Formation of cyclophosphamide specific DNA adducts in hematological diseases. Pediatr Blood Cancer. 2012;58(5):708-14.

33. Souliotis VL, Dimopoulos MA, Sfikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res. 2003;9(12):4465-74.

34. Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest. 1986;77(2):545-50.

35. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A. 1987;84(14):5024-8.

36. Gupta-Burt S, Shamkhani H, Reed E, Tarone R, Allegra C, Pai L, et al. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev. 1993;2(3):229-34.

37. Nel I, Gauler TC, Eberhardt WE, Nickel AC, Schuler M, Thomale J, et al. Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment. Br J Cancer. 2013;109(5):1223-9.

38. Zimmermann M, Li T, Semrad TJ, Wu CY, Yu A, Cimino G, et al. Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. Mol Cancer Ther. 2020;19(4):1070-9.

39. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, et al. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011;129(6):1425-34.

40. Balbo S, Hashibe M, Gundy S, Brennan P, Canova C, Simonato L, et al. N2-ethyldeoxyguanosine as a potential biomarker for assessing effects of alcohol consumption on DNA. Cancer Epidemiol
Biomarkers Prev. 2008;17(11):3026-32.

41. Lucas A, O'Neal S, Santos C, White T, Zamboni W. A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues. J Pharm Biomed Anal. 2016;119:122-9.

42. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Physiol. 2020;598(18):3793-801.

43. Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, Shohet RV. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2006;290(3):H1098-102.

44. Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation. 2004;110(18):2869-74.

45. van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer. 1999;79(1):108-13.

46. Doroshow JH, Locker GY, Ifrim I, Myers CE. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J Clin Invest. 1981;68(4):1053-64.

47. Matsumura N, Zordoky BN, Robertson IM, Hamza SM, Parajuli N, Soltys CM, et al. Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes. Cardiovasc Res. 2018;114(10):1350-9.

48. Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.